We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-6.35%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$11.4B
AUM Growth
-$782M
Cap. Flow
+$157M
Cap. Flow %
1.38%
Top 10 Hldgs %
87.68%
Holding
124
New
6
Increased
21
Reduced
9
Closed
4

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$234M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$100M
3
ASND icon
Ascendis Pharma A/S
ASND
+$10.6M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$9.37M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$6.88M

Top Sells

Rank Stock Value
1
ACOR
Acorda Therapeutics
ACOR
+$69.3M
2
DERM
Dermira, Inc.
DERM
+$14.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$13.5M
4
EXEL icon
Exelixis
EXEL
+$11M
5
CERS icon
Cerus
CERS
+$9M

Sector Composition

Rank Sector Weight
1 Healthcare 92.56%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBAY
51
DELISTED
Cymabay Therapeutics
CBAY
$7.44M 0.07%
1,291,775
-121,724
-9% -$518K
RIGL icon
52
Rigel Pharmaceuticals
RIGL
$734M
$6.88M 0.06%
251,888
– –
INSM icon
53
Insmed
INSM
$22.5B
$6.86M 0.06%
400,000
– –
AGIO icon
54
Agios Pharmaceuticals
AGIO
$2.1B
$6.62M 0.06%
128,666
– –
MGNX icon
55
MacroGenics
MGNX
$238M
$6.37M 0.06%
363,676
– –
CBIO
56
Crescent Biopharma
CBIO
$561M
$6.29M 0.06%
5,633
+1,821
+48% +$1.5M
CFRX
57
DELISTED
ContraFect Corporation
CFRX
$5.87M 0.05%
5,057
– –
STML
58
DELISTED
Stemline Therapeutics, Inc.
STML
$5.83M 0.05%
633,497
– –
RNAC icon
59
Cartesian Therapeutics
RNAC
$219M
$5.76M 0.05%
9,660
+3,803
+65% +$1.68M
ASMB icon
60
Assembly Biosciences
ASMB
$494M
$5.16M 0.05%
20,833
– –
FSTX
61
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$5.05M 0.04%
93,286
+38,461
+70% +$1.78M
SYRE icon
62
Spyre Therapeutics
SYRE
$8.45B
$4.38M 0.04%
45,515
+37,916
+499% +$5.24M
ALBO
63
DELISTED
Albireo Pharma Inc
ALBO
$4.12M 0.04%
+200,000
New +$4.1M
LUMO
64
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$3.67M 0.03%
+55,556
New +$6.88M
NBRV
65
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$3.67M 0.03%
1,400
– –
EPZM
66
DELISTED
Epizyme, Inc
EPZM
$3.51M 0.03%
232,481
– –
OVID icon
67
Ovid Therapeutics
OVID
$427M
$3.5M 0.03%
+333,333
New +$4.35M
RARX
68
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$3.33M 0.03%
177,952
– –
ADMS
69
DELISTED
Adamas Pharmaceuticals
ADMS
$3.02M 0.03%
172,630
– –
ANAB icon
70
AnaptysBio
ANAB
$1.54B
$2.81M 0.02%
117,211
-32,789
-22% -$824K
ZGNX
71
DELISTED
Zogenix, Inc.
ZGNX
$2.69M 0.02%
185,290
-196,649
-51% -$2.47M
ALDR
72
DELISTED
Alder Biopharmaceuticals
ALDR
$2.49M 0.02%
217,328
– –
NTRA icon
73
Natera
NTRA
$36.1B
$2.48M 0.02%
228,676
– –
NVAX icon
74
Novavax
NVAX
$1.22B
$2.3M 0.02%
+100,000
New +$1.96M
AKTX
75
Akari Therapeutics
AKTX
$14.5M
$2.29M 0.02%
621
– –
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2017 Portfolio in Review

As of Q2 2017, Baker Bros. Advisors held 124 positions worth $11.4B, down 6.4% from $12.2B the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Baker Bros. Advisors's Q2 2017 filing shows 6 new, 21 increased, 9 reduced and 4 closed positions. Its largest new stake was Lumos Pharma, Inc. Common Stock: 55,556 shares worth $3.67M. The largest sale was Acorda Therapeutics, an estimated $69.3M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q2 2017 buy was Lumos Pharma, Inc. Common Stock: 55,556 shares worth $3.67M.
  • Baker Bros. Advisors added most to Alexion Pharmaceuticals in Q2 2017, an estimated $234M increase.
  • Baker Bros. Advisors's biggest Q2 2017 reduction was Neurocrine Biosciences, cutting an estimated $13.5M.
  • Baker Bros. Advisors fully exited Acorda Therapeutics in Q2 2017, selling an estimated $69.3M.
  • Baker Bros. Advisors's ten largest holdings make up 88% of its $11.4B portfolio in Q2 2017.
  • Baker Bros. Advisors opened 6 new positions and closed 4 in Q2 2017.
  • Baker Bros. Advisors's portfolio value fell 6.4% quarter-over-quarter to $11.4B.

Based on Baker Bros. Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.